Gilead (GILD) Issues Strong '7977 Update, Shares Move Higher

Shares of Gilead Sciences, Inc. (Nasdaq: GILD) are moving higher Friday following positive data related to its experimental hepatitis C (HCV) treatments.

On the company's fourth-quarter earnings conference call late Thursday, Gilead's scientific chief Norbert Bischofberger said trials of PSI-7977 in patients with genotype 1 HCV showed no signs of the virus after being on the drug for four weeks.

PSI-7977 was said to cure patients with genotypes 2 and 3, according to earlier studies.

Competitors in the field include Merck (NYSE: MRK), Vertex Pharma (NYSE: VRTX), Bristol-Myers Squibb (NYSE: BMY), Idenix Pharma (Nasdaq: IDIX) and Achillion Pharma (Nasdaq: ACHN).

A number of analysts issued comments on Gilead following the call. For more color, click here.

Gilead shares last traded at $54.40, up 10.3 percent from Thursday's close.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Seanergy Maritime prices €100M bond offering on Euronext Athens
• Lyft to acquire Serveo's bikeshare business in Spain